ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in ProPhase Labs, Inc. (NASDAQ:PRPH) by 1.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 618,763 shares of the company’s stock after acquiring an additional 9,416 shares during the period. Vanguard Group Inc. owned 3.43% of ProPhase Labs worth $4,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of ProPhase Labs to a “sell” rating in a research report on Wednesday, June 26th.

ProPhase Labs Stock Up 10.6 %

Shares of NASDAQ:PRPH opened at $2.50 on Monday. The business has a fifty day moving average of $3.49 and a two-hundred day moving average of $4.68. The company has a quick ratio of 1.73, a current ratio of 1.88 and a debt-to-equity ratio of 0.31. The stock has a market cap of $47.70 million, a P/E ratio of -2.31 and a beta of -0.10. ProPhase Labs, Inc. has a 52-week low of $2.04 and a 52-week high of $7.48.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.